This study is currently not recruiting participants.
A Phase II Single-Blind Placebo-Controlled Sequential Treatment Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Donepezil with Solifenacin in Patients with Alzheimer's Disease Type Dementia
M
Martin Farlow, MD
Primary Investigator
Not Recruiting
50 years - 79 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.
Detailed description of study
The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Alzheimer's Disease Type Dementia
Age:
50 years - 79 years
Gender: All
Updated on
01 Aug 2024.
Study ID: 1405058990
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
